Login to Your Account



Add-on nauseam: Change epilepsy drugs vocabulary, pleads Briviact researcher

By Randy Osborne
Staff Writer

Friday, February 19, 2016

The principal investigator for the original proof-of-concept study with just-approved epilepsy drug Briviact told BioWorld Today she's campaigning to get the FDA to cut the "add-on" description for such therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription